

16 May 2023

## Cancer treatments 2022-2023

Please may you tell me how many patients were initiated with each drug and indication/form below:

| Title   | NICE TA Codes |
|---|---------------|
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer  | TA831         |
| Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer  | TA693         |
| Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer  | TA620         |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA598         |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection   | TA761         |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer   | TA653         |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer   | TA654         |
| Acalabrutinib for treating chronic lymphocytic leukaemia  | TA689         |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation   | TA798         |

16 May 2023

|   |       |
|---|-------|
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies  | TA704 |

**Level of Granularity: across all trusts combined.**

**Data periods:**

- Monthly from January 2022 to February 2023
- Total yearly 2020, 2021 and 2022, for each drug and indication/form above

16 May 2023

| Month        | Olaparib (Prostate) | Olaparib plus Bevacizumab | Olaparib Ovarian, Fall Tube, Peritoneal | Osimertinib NSCLC | Durvalumab NSCLC | Trastuzumab Deruxtecan Breast |
|--------------|---------------------|---------------------------|---|-------------------|------------------|-------------------------------|
| January 22   | 0                   | 0                         | <5                                      | 0                 | 0                | 0                             |
| February 22  | 0                   | 0                         | <5                                      | <5                | <5               | 0                             |
| March 22     | 0                   | 0                         | <5                                      | <5                | <5               | 0                             |
| April 22     | 0                   | 0                         | 0                                       | 0                 | <5               | 0                             |
| May 22       | 0                   | 0                         | 0                                       | <5                | <5               | 0                             |
| June 22      | 0                   | 0                         | <5                                      | <5                | 0                | 0                             |
| July 22      | 0                   | 0                         | <5                                      | 0                 | 0                | 0                             |
| August 22    | 0                   | 0                         | 0                                       | 0                 | 0                | 0                             |
| September 22 | 0                   | 0                         | <5                                      | 0                 | 0                | 0                             |
| October 22   | 0                   | 0                         | <5                                      | <5                | <5               | <5                            |
| November 22  | 0                   | 0                         | <5                                      | <5                | 0                | 0                             |
| December 22  | 0                   | 0                         | 0                                       | 0                 | 0                | 0                             |
| January 23   | 0                   | 0                         | <5                                      | 0                 | 0                | 0                             |
| February 23  | 0                   | 0                         | 0                                       | 0                 | <5               | 0                             |
| 2022         | 0                   | 0                         | 11                                      | 8                 | 6                | <5                            |
| 2021         | 0                   | 0                         | 15                                      | 6                 | 0                | <5                            |
| 2020         | 0                   | 0                         | 16                                      | 5                 | 0                | 0                             |

**Please note:**

- Return from Cancer Services does not include Leukemia patients. The information requested is not collated centrally and an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as

**16 May 2023**

£450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

- Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.